Concepedia

Jeffrey M. Bozarth

JM

29

Publications

1.1K

Citations

20

H-Index

1994

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Wilmington University

DuPont (United States)

Bristol-Myers Squibb (India)

Syngene International (India)

Jeffrey M. Bozarth is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicine, and drug discovery.

Top concepts

Publications per year

1994–2021

29

Publications

29

Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.

Shaker A. Mousa, Jeffrey M. Bozarth, Mark S. Forsythe et al. · Circulation · 1994 · 103 citations · Full text

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte et al. · Journal of Medicinal Chemistry · 2021 · 93 citations · Full text

Design, Synthesis, and Evaluation of Radiolabeled Integrin α <sub> <i>v</i> </sub> β <sub>3</sub> Receptor Antagonists for Tumor Imaging and Radiotherapy

Thomas D. Harris, Shirley Kalogeropoulos, Tiffany Nguyen et al. · Cancer Biotherapy and Radiopharmaceuticals · 2003 · 82 citations

Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors

Mimi L. Quan, Pancras C. Wong, Cailan Wang et al. · Journal of Medicinal Chemistry · 2014 · 76 citations · Full text

, , +18

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits

Pancras C. Wong, Earl J. Crain, Jeffrey M. Bozarth et al. · Journal of Thrombosis and Haemostasis · 2021 · 58 citations · Full text

, , +9

Rows per page

1–5 of 29